跳至主要内容
临床试验/NCT02225080
NCT02225080已完成不适用

Duragen® Secure Post Marketing Clinical Follow-up (PMCF)

Integra LifeSciences Corporation5 个研究点 分布在 4 个国家目标入组 100 人开始时间: 2014年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
5
主要终点
Patient's Outcome

研究概览

简要总结

The purpose of this study is to gather information about post-market performance of DuraGen Secure.The aim of this post market clinical follow-up (PMCF) is to obtain post market clinical data to evaluate the presence of unintended residual risks associated with the use of DuraGen Secure that were not anticipated or identified in the animal studies, bench studies or clinical evaluation report.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient who have undergone a neurosurgical procedure where DuraGen® Secure has been implanted

排除标准

  • Patient who does not agree to allow collection of his/her medical data

结局指标

主要结局

Patient's Outcome

时间窗: Day 30

Patient outcome from the procedure (recovered without sequelae, ongoing with medical intervention, ongoing with surgical intervention, deceased, other)

次要结局

  • Occurence of Adverse Event(Between days 15-30)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验